Overview of Science 37 and Decentralized Clinical Trials. Presenters: Stuart Bennett, Sr Director, Business Development 18 years Life Science experience, service delivery, marketing and commercial experience. Joined Science 37 in 2021 to help accelerate clinical research by enabling universal access for patients and providers, anywhere. Katie McEnery, Director, Technology Solutions 8 years clinical research experience, primarily operational experience in clinical development spanning patient-focused technology solutions, CRO and large pharma. Alan O’Connor, Vice President, Business Development 15 years Life Science experience, covered full life-cycle from commercial activities directly with prescribing consultants, manufacturing operations and clinical development. Science 37 Team Introductions o Science 37 Company Introduction o Science 37 General Capabilities o Traditional model vs Science 37 model o Patient Journey o Science 37 Operating System o Agile Configurations o Questions/Discussion

1. © 2022 Science 37. All rights reserved. This material is confidential and proprietary to Science 37
and shall not be distributed, edited or modified in any way without Science 37's advance written consent.
The Operating System that enables Agile Clinical Trials™
Any Patient.
Any Provider.
Anywhere.*
*Considerations must be taken into account such as regulatory acceptance and internet/
Wi-Fi availability.

2. This material is confidential and proprietary to Science 37® and shall not be distributed, edited, or modified in any way without written consent from Science 37.
Meet the Team.
Stuart Bennett, Sr Director, Business Development
18 years Life Science experience, service delivery, marketing and commercial experience.
Joined Science 37 in 2021 to help accelerate clinical research by enabling universal access
for patients and providers, anywhere.
Katie McEnery, Director, Technology Solutions
8 years clinical research experience, primarily operational experience in clinical
development spanning patient-focused technology solutions, CRO and large
pharma.
Alan O’Connor, Vice President, Business Development
15 years Life Science experience, covered full life-cycle from commercial activities
directly with prescribing consultants, manufacturing operations and clinical
development.

3. This material is confidential and proprietary to Science 37® and shall not be distributed, edited, or modified in any way without written consent from Science 37.
o Science 37 Team Introductions
o Science 37 Company Introduction
o Science 37 General Capabilities
o Traditional model vs Science 37 model
o Patient Journey
o Science 37 Operating System
o Agile Configurations
o Questions/Discussion
Agenda.
3

4. © 2022 Science 37. All rights reserved. This material is confidential and proprietary to Science 37
and shall not be distributed, edited or modified in any way without Science 37's advance written consent.
Unparalleled Experience in DCT and Agile Trials.
21x
Faster Trial Enrollment
28%
Greater Patient Retention
3x
More Diversity
580k+
Participants Engaged
125+
Trials Launched
95+
Countries Supported
45+
Languages (on Platform)
81%
Repeat Customers
(from 2020 to 2021)
34,000+
Physician Providers
(Contracted for Research)
Science 37 Internal case study, reports, and estimates
4
© 2022 Science 37. All rights reserved. This material is confidential and proprietary to Science 37
and shall not be distributed, edited or modified in any way without Science 37's advance written consent.

5. © 2022 Science 37. All rights reserved. This material is confidential and proprietary to Science 37
and shall not be distributed, edited or modified in any way without Science 37's advance written consent.
The Traditional Site Model is Ready for Change.
The clinical trial model
has not changed in
60-90 years.
Patients
Contract
Research
Associates
Sites
Sponsor
Coordinator / Investigator / Nurse
5
14%
Non-white
representation6
70%
Patient
retention rate3
3%
Of physicians
participate1
8%
Of patients
participate4
Disjointed processes, disconnected technologies,
and redundant oversight lead to:
80%
Delayed from
poor enrollment5
31.4 Wks
Avg start up time2
Limited
Participation
Slow & Inefficient
Execution
Poor Retention &
Representation
1 https://physicians.dukehealth.org/articles/practice-based-clinical-trials-benefits-and-barriers
2. stat https://www.globenewswire.com/news-release/2018/03/07/1417625/0/en/First-Comprehensive-
Clinical-Site-Initiation-Benchmark-Developed-by-Tufts-Center-for-the-Study-of-Drug-Development-Finds-
Study-Startup-Is-Lengthy-and-Inefficient.html
3.https://mdgroup.com/blog/the-complete-guide-to-improving-patient-retention-in-clinical-trials
4. https://www.asco.org/about-asco/press-center/news-releases/studies-provide-insight-factors-clinical-trial-participation
5. https://www.clinicaltrialsarena.com/marketdata/featureclinical-trial-patient-recruitment
6. https://www.scientificamerican.com/article/clinical-trials-have-far-too-little-racial-and-ethnic-diversity/

6. © 2022 Science 37. All rights reserved. This material is confidential and proprietary to Science 37
and shall not be distributed, edited or modified in any way without Science 37's advance written consent.
The Science 37 Agile Delivery Model.
Send patients anywhere
for procedures,
not just at the site.
Incorporate KOLs
with traditional sites,
or supplement with DCT.
Connect any patient
with any provider—
without boundaries.
Recruit anyone and
conduct visits anywhere,
beyond the 8%. PoC
Telemedicine Site
Home
Improve enrollment, retention, and representation with a model that drives
compliance, high-quality data, and ultimately, faster, more efficient trials.
Patients
Providers
6

7. © 2022 Science 37. All rights reserved. This material is confidential and proprietary to Science 37
and shall not be distributed, edited or modified in any way without Science 37's advance written consent.
Science 37 Drives Efficiency in Clinical Research.
Traditional Clinical Trial
7
Science 37 Agile Trial
96%
Patient
retention*
3x
More
diversity*
21x
Faster
enrollment*
Accelerate
Trial Timelines
Improve Retention
& Representation
Reach any Patient.
Any Provider.
Limited
Participation
Slow & Inefficient
Execution
Poor Retention &
Representation
14%
Non-white
representation6
70%
Patient
retention rate3
3%
Of physicians
participate1
8%
Of patients
participate4
80%
Delayed from
poor enrollment5
31.4 Wks
Avg start up time2
*Science 37 Case Study Results
*Considerations must be taken into account such as
regulatory acceptance and internet/Wi-Fi availability.
100%
Providers can
participate
100%
Patients can
participate
Up
to
Up
to
1 https://physicians.dukehealth.org/articles/practice-based-clinical-trials-benefits-and-barriers
2. stat https://www.globenewswire.com/news-release/2018/03/07/1417625/0/en/First-Comprehensive-Clinical-Site-Initiation-Benchmark-Developed-by-Tufts-
Center-for-the-Study-of-Drug-Development-Finds-Study-Startup-Is-Lengthy-and-Inefficient.html
3.https://mdgroup.com/blog/the-complete-guide-to-improving-patient-retention-in-clinical-trials
4. https://www.asco.org/about-asco/press-center/news-releases/studies-provide-insight-factors-clinical-trial-participation
5. https://www.clinicaltrialsarena.com/marketdata/featureclinical-trial-patient-recruitment
6. https://www.scientificamerican.com/article/clinical-trials-have-far-too-little-racial-and-ethnic-diversity/
12 Wks
Faster
start-up*
Up
to

8. © 2022 Science 37. All rights reserved. This material is confidential and proprietary to Science 37
and shall not be distributed, edited or modified in any way without Science 37's advance written consent.
Reach Any Patient. Any Provider. Anywhere.
Traditional Site Representation: Science 37 Representation:
Less than 8%
of the population1
Up to 100%
of the population*
Entire Countries
launched at the same time
21x
Faster Enrollment*
3x
More Diversity*
In previous studies,
Science 37 has delivered:
1 https://www.asco.org/about-asco/press-center/news-releases/
studies-provide-insight-factors-clinical-trial-participation
*Considerations must be taken into account such
as regulatory acceptance and internet/Wi-Fi availability.
*Science 37 Case Study Results 8

9. © 2022 All rights reserved | Confidential | For Science 37® use only 9
Technology Platform
Patient
Pre-Screening
v
SCIENCE 37 TEAM
The Science 37 team of Principal and Sub-Investigators, Patient Representatives, Mobile Healthcare Providers, and Clinical
Research Coordinators orchestrate the entire process—improving enrollment and retention.
Medical
Screening
eConsent
Screening
Enrollment
Randomization
Shipment of IMP
Study
Period
End of
Study
Adaptive Outreach Strategy
• Advocacy Groups
• Digital Media
• Health Websites
• Provider Network
• Science 37 Database
• Strategic Partners
• And More
Science 37 Participant Journey.

10. © 2022 All rights reserved | Confidential | For Science
37® use only
10
Science 37: The Most Comprehensive End-to-End Platform.
Participants/
Caregivers
Investigators
Community
Providers
Nursing
Coordinators
Orchestrating All Study Conduct Activities Across Stakeholders
• Unified Stakeholder Journey
• Enables Greater Compliance
Net Benefits
• Generates
High-Fidelity Data
Digitized Schedule of Assessments
eConsent Scheduling Telemedicine eCOA
Remote On Premise
Hybrid
Progress
Notes
Devices AEs/SAEs
Other
Endpoints

11. © 2022 Science 37. All rights reserved. This material is confidential and proprietary to Science 37
and shall not be distributed, edited or modified in any way without Science 37's advance written consent.
The Science 37 Operating System.
Science 37
Operating
System
Workflow Orchestration
Evidence Generation
Data Harmonization
Patient Communities
Remote Coordinators
Telemedicine Investigators
Community Providers
Mobile Nursing
Data & Devices
UNIFIED
TECHNOLOGY
STANDARDIZED
PROCESSES
CENTRALIZED
NETWORKS
11
Greater Consistency and Compliance. Less Data Variability.

12. © 2022 Science 37. All rights reserved. This material is confidential and proprietary to Science 37
and shall not be distributed, edited or modified in any way without Science 37's advance written consent.
Agile Configurations Enable Any Study.
Science 37 Platform Trial Orchestration Sole Provider
Full DCT
(Fully responsible for delivery of the
trial)
Metasite™
(Responsible for a portion of
enrollment as a virtual site)
Technology
(Configure the OS to enable
elements of the trial)
Technology
Configurations
Patient Engagement eConsent eSource (eCOA, eCRF) Telemedicine Data & Devices
Network
Configurations
Patient Communities Remote Coordinators Mobile Nursing
Telemedicine
Investigators
Community Providers
Study
Configurations
Any Indications Early Phase Pivotal Studies Real-World Evidence Long-Term Follow-up
12

13. © 2022 All rights reserved | Confidential | For Science 37® use only 13
The Metasite™ Accelerates Patient Enrollment Globally.
• The association between
disease prevalence and poverty
rates varies by level of
urbanization
• In this example, higher rates of
disease prevalence are
represented by the darker
colors
• In traditional trials, sponsors
would deploy investigator sites
in areas of high population
density and notable academic
centers
Patient distribution and disease
prevalence is not uniform:
< 8.1% 8.8 < 9.5% 9.9%
8.1 < 8.8% 9.5 < 9.9%
LEGEND:

14. © 2022 All rights reserved | Confidential | For Science 37® use only 14
The Metasite™ Accelerates Patient Enrollment Globally.
• The black dots represent typical
site distribution within the US
• Each dot represents a physical
site and 50 mile recruitment
radius
• The sites only cover 2% of the
US population
• This restricts access for 98% of
the population who reside more
than 50 miles from a site
Typical site distribution creates a
bottleneck to recruitment:
< 8.1% 8.8 < 9.5% 9.9%
8.1 < 8.8% 9.5 < 9.9%
LEGEND:
Traditional Site Representation:
Population within 50 miles of site.

15. © 2022 All rights reserved | Confidential | For Science 37® use only 15
The Metasite™ Accelerates Patient Enrollment Globally.
Traditional Site Representation:
Population within 50 miles of site.
Science 37 Metasite Representation:
Any Patient, Any Provider, Anywhere.
• Metasite™ complements a
traditional site model
• Provides universal access
to patients
• Accelerates enrollment by
accessing a broader
patient population
• Accommodates patient
choice with at-home
participation
The Metasite™ delivers patient
access without boundaries:

16. © 2022 Science 37. All rights reserved. This material is confidential and proprietary to Science 37
and shall not be distributed, edited or modified in any way without Science 37's advance written consent.
What our Patients Say.
It was an easy experience. The person
that came to take my sample was very
professional and informative as to
what to expect in my procedure and
with the study. I would do it again.
“
Simple
and
hassle-free.
“
It was a great
experience.
The coordinators were
friendly and informative
—the process was
navigated easily.
“
The study was so easy to participate in
and the people who I interacted with
were very helpful, respectful and
knowledgeable.
“
The entire
process
was
very easy.
“
16

17. © 2022 Science 37. All rights reserved. This material is confidential and proprietary to Science 37
and shall not be distributed, edited or modified in any way without Science 37's advance written consent.
What our Sponsors Say.
The process was user-friendly both at
the participant site and at the virtual site.
Beyond the technology, we were able to
get everything from the patients on time.
“ The Science 37 virtual offering
puts the patient experience first
from the very first contact.
“
Science 37 delivers a model that truly
supports patient preference—providing
access through the site or through a
DCT model. The patient’s choice is
front and center.
“ Science 37 allows us to enroll
patients who don’t traditionally
participate in trials, decreasing
burden on patients and site,
improving diversity and reach.
“
17

18. © 2022 Science 37. All rights reserved. This material is confidential and proprietary to Science 37
and shall not be distributed, edited or modified in any way without Science 37's advance written consent.
Thank you.
Science37
Science37.com
@Science37 Science37
Thank you.

19. © 2022 Science 37. All rights reserved. This material is confidential and proprietary to Science 37
and shall not be distributed, edited or modified in any way without Science 37's advance written consent.
Supporting Studies Globally.
Technology Platform
Technology Platform + Centralized Networks
Visualization depicts Mobile Nurses and Telemedicine Investigators
deployed and/or contracted to deploy as of July 2021.
95+
Countries
Source: Deployment and/or ability to deploy Science 37 technology platform as of December 31, 2021
19

20. © 2022 All rights reserved | Confidential | For Science 37® use only 20
Models in Use by Leading Sponsors.
Community-Based Procedures
03
Enroll faster, without site geography limitations.
Leverage community providers to perform study procedures.
Metasite & Site Enablement
02
Supplement your traditional site network with a virtual site
and centralize data capture using the Science 37 OS.
Direct Data Capture at Traditional Sites on Science 37’s Platform
Science 37 Metasite
Science 37
Operating
System
Metasite with EDC
01
Supplement your traditional site network with a virtual site
to fill in the white space and accelerate enrollment.
Traditional Site-based Trials Science 37 Metasite
EDC
Science 37
Operating
System
Recruitment Enrollment Engagement Conduct
Science 37 Community-based Practices
(Primary Care, Labs, etc.)
Science 37
Operating System
Site Initiated; Remote Management
04
Enroll patients via traditional sites. Reduce patient burden
via remote or home-based visits.
Recruitment Enrollment Engagement Home Visit
Science 37
Science 37
Operating System
Traditional Site-based Trials
Bring Your Own Investigator
05
Pinpoint patients. Engage patient and community provider to
enroll the patient with community provider as Sub-Investigator.
Recruitment Enrollment Engagement Conduct
Science 37
Metasite
Science 37
Operating System
Rare Patient
Database
Community
Provider
Long Term Follow-Up
06
Parent study sites hand-off the follow-up to a virtual site
to reduce traditional site burden.
Recruitment Engagement Conduct Long-Term
Parent Sites
Metasite
Science 37
Operating
System

21. © 2022 All rights reserved | Confidential | For Science 37® use only 21
Maximize ROI.
3-4 Months
Shorter Startup
+
3-6 Months
Shorter Enrollment
OVERALL TIME SAVINGS
6-10 Months
Overall study time
EFFICIENCY
Avg cash burn / mo.
Projected among PIII trials across TAs
$3.3M
+ $16.7M Avg revenue / mo.
Projected among PIII trials across TAs in 2023
$20.0M Monthly Opportunity Cost
Science 37 Cost / Revenue Assumptions
$120M – $200M
Potential
Opportunity Cost Savings
x =
For example:
Science 37 Enables Opportunity Cost Savings.
1. https://www.evaluate.com/
2. https://www.globaldata.com/data-insights/healthcare
*Science 37 Case Study/